Shionogi Funding Research to Develop World’s First Drug for Preventing Postoperative Metastasis of Lung Cancer

Clinical research investigating whether the atrial natriuretic peptide (ANP) could become the world’s first “anti-metastatic agent” for preventing relapse and metastasis following lung cancer surgery, is moving forward at the National Cerebral and Cardiovascular Center (NCVC) and other facilities. Joint research on the use of ANP in combination with anticancer drugs is scheduled to begin later this year. Shionogi is providing funding for the research, dubbed “JANP study”. It aims to use research findings to develop a new human ANP (hANP) drug in the cancer field.

ANP is a cardiac hormone discovered in Japan in 1984. The α-hANP carperitide is used only in Japan for the treatment of heart failure. Takashi Nojiri, head of the NCVC’s peptide drug development laboratory and the lead investigator of the JANP study, conducted a retrospective analysis of data from patients who received low-dose ANP (0.025 µg/kg/min) by IV drip infusion over a three-day period starting during radical surgery for non-small cell lung cancer (NSCLC). Dr Nojiri found that patients who underwent surgery and received ANP had a two-year relapse-free survival rate of 91%, as compared to 67% for patients who underwent surgery alone.